Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

– Conference Call and Webcast Today at 4:30 p.m. EST

PASADENA, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24arwr&src=ctag” target=”_blank”gt;$arwrlt;/agt;–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial
results for its fiscal 2019 first quarter ended December 31, 2018. The
company is hosting a conference call at 4:30 p.m. EST to discuss results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadpharma.com/events.cfm.
For analysts that wish to participate in the conference call, please
dial 855-215-6159 or 315-625-6887 and provide Conference ID 3194897.

A replay of the webcast will be available on the company’s website
approximately two hours after the conclusion of the call and will remain
available for 90 days. An audio replay will also be available
approximately two hours after the conclusion of the call and will be
available for 3 days. To access the audio replay, dial 855-859-2056 or
404-537-3406 and provide Conference ID 3194897.

Selected Fiscal 2019 First Quarter and Recent Events

  • Signed a license agreement with Janssen Pharmaceuticals, Inc., part of
    the Janssen Pharmaceuticals Companies of Johnson & Johnson, for
    ARO-HBV (now JNJ-3989) and a collaboration agreement for up to three
    RNAi therapeutic candidates that use our proprietary TRiMTM
    platform against new targets to be selected by Janssen

    • The total potential deal value is approximately $3.7 billion plus
      royalties on commercial sales
    • Received $175 million as an upfront payment and received $75
      million in the form of an equity investment by Johnson & Johnson
      Innovation – JJDC, Inc., at a price of $23.00 per share of
      Arrowhead common stock
  • Presented clinical data on ARO-AAT at the AASLD Liver Meeting 2018
    demonstrating:

    • Three monthly doses of 300 mg ARO-AAT led to reductions in serum
      alpha-1 antitrypsin to below the level of quantitation in 100% of
      subjects
    • Reductions were sustained for greater than 14 weeks indicating
      that quarterly or less frequent dosing appears feasible
    • Single and multiple doses of ARO-AAT appeared to be well-tolerated
      at all doses tested
  • Presented clinical data on ARO-HBV (now JNJ-3989) at the AASLD Liver
    Meeting 2018 demonstrating:

    • Mean HBsAg reduction of -1.9 Log10 (-98.7%) with a range of -1.3
      Log10 (-95.0%) to -3.8 Log10 (-99.98%)
    • ARO-HBV (now JNJ-3989) appeared to be well-tolerated at monthly
      doses up to 400 mg
  • Hosted an R&D Day in October 2018 to discuss in more detail our
    emerging pipeline of RNAi therapeutics that leverage the TRiMTM
    platform
  • Began dosing in a Phase 1 single and multiple dose study of ARO-ANG3,
    a subcutaneously administered RNAi therapeutic targeting angiopoietin
    like protein 3, being developed as a potential treatment for patients
    with dyslipidemias and metabolic diseases
  • Filed for regulatory clearance to begin a Phase 1 study of ARO-APOC3,
    a subcutaneously administered RNAi therapeutic targeting
    apolipoprotein C-III, being developed as a potential treatment for
    patients with hypertriglyceridemia

Selected Fiscal 2019 First Quarter Financial Results

 
ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)
     
Three Months Ended December 31,

OPERATING SUMMARY

2018 2017
 
REVENUE $ 34,657,896 $ 3,509,821
OPERATING EXPENSES
Research and development 17,572,043 12,919,618
General and administrative expenses   6,139,709   4,403,551
TOTAL OPERATING EXPENSES   23,711,752   17,323,169
OPERATING INCOME (LOSS) 10,946,144 (13,813,348 )
OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES   1,091,109   614,470
NET INCOME (LOSS) $ 12,037,253 $ (13,198,878 )
 
NET INCOME (LOSS) PER SHARE (DILUTED) $ 0.13 $ (0.18 )
WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED)   95,590,183   74,831,415
 

FINANCIAL POSITION SUMMARY

December 31, September 30,
2018 2018
CASH AND CASH EQUIVALENTS $ 189,772,981 $ 30,133,213
SHORT-TERM INVESTMENTS 53,980,307 46,400,176
LONG-TERM INVESTMENTS   59,595,287  
TOTAL CASH RESOURCES (CASH AND INVESTMENTS)   303,348,575   76,533,389
OTHER ASSETS   37,598,813   35,076,562
TOTAL ASSETS   340,947,388   111,609,951
TOTAL CURRENT DEFERRED REVENUE 124,925,638 600
TOTAL LONG TERM DEFERRED REVENUE 33,171,402
OTHER LIABILITIES   11,350,317   16,368,350
TOTAL LIABILITIES   169,447,357   16,368,950
TOTAL STOCKHOLDERS’ EQUITY   171,500,031   95,241,001
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 340,947,388 $ 111,609,951
 
SHARES OUTSTANDING 92,591,457 88,502,302
 

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.

For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform
Act:

This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the likelihood and
timing of the receipt of future milestone and licensing fees, the future
success of our scientific studies, our ability to successfully develop
and commercialize drug candidates, the timing for starting and
completing clinical trials, rapid technological change in our markets,
and the enforcement of our intellectual property rights. Our most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q
discuss some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no obligation
to update or revise forward-looking statements to reflect new events or
circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Contacts

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
[email protected]

Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
[email protected]
www.lifesciadvisors.com

error: Content is protected !!